INS and cancer: Six of the 38 (16%) experienced a double digit drop in fasting insulin, 8 of 9 (89%) dropped from the high-risk category to a lower risk level, 17 (52%) lowered insulin levels sufficiently to reduce their cancer risk severity category, 11 (33%) changed little and stayed in the same risk category and 2 move up one risk category (Table 5).